PB1883: IMPLANTATION AND LONG-TERM USE OF PERIPHERALLY-INSERTED CENTRAL CATHETER ARE SAFE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKAEMIA

• DOI: 10.1097/01.hs9.0000974356.44630.7c
• Publication Date: 2023-08-08T17:00:34Z
• Authors: Tomáš Szotkowski; Martin Čerňan; Lucia Vráblová; Monika Labudíková; Tomáš Papajík
• Keywords: Venous access; Central venous catheter; Reimbursement

Topic: 4. Acute myeloid leukemia - Clinical Background: At diagnosis, acute promyelocytic leukaemia (APL) is associated with high risk of bleeding complications due to coagulopathy and thrombocytopenia. In current guidelines, it explicitly stated that the introduction central venous catheter should be avoided in this initial phase. However, patients absolutely need high-quality access for administration both antitumor supportive treatment. A peripherally inserted (PICC) a intended medium long-term use. Its implantation use are safe hands experienced personnel. We started PICC implementation program at our institution 2016. After gaining necessary experience, we also implanting type leukaemia. Due lower implantation, decided prefer APL as well. Aims: Retrospective analysis single experience all consecutive newly diagnosed over past 5 years. Methods: have treated total 13 since 2017. was used them from beginning induction There were 8 women men an median age 60 (24-73) The first five combination ATRA chemotherapy, others according ATRA-ATO protocol. selection treatment protocol determined by currently valid recommendation reimbursement rules within framework health insurance. usually implanted on second day hospitalization (7 patients), less often (3 patients). two group, performed 6th 5th day, respectively. punctured vein brachial or basilic 10 cases, axillary (with longer subcutaneous tunnelling) 3 patients. 2-lumen 5F more times – including chemotherapy), 1-lumen 4F 6 times. level platelets 55 (20 118) x 109/l. All had typical APL. Results: 7 patients, entire duration extracted after its completion. 202 (159-298) days. Three continue 116, 151 262 before end patient group 30 days local inflammation entry site, seventh 31 fever unknown origin. One died during (ATRA/ATO) respiratory failure caused COVID-19 pneumonia. addition above, noticed only one complication, which did not require extraction. It short partial thrombosis around 26 implantation. None complication Summary/Conclusion: Our 5-year suggests team, device providing care leukaemia, most critical phase Supported IGA_LF_UP_2023_005 MZ ČR RVO (FNOL, 00098892). Keywords: leukemia, Central